

NEUROCRINE BIOSCIENCES INC  
Form SC 13G/A  
April 19, 2001

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. 1)

Neurocrine Biosciences, Inc.  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

64125C109  
(CUSIP Number)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

13G

CUSIP NO. 64125C109

- 1) NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Wells Fargo & Company  
Tax Identification No. 41-0449260

- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) [ ]  
(b) [ ]

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form SC 13G/A

3) SEC USE ONLY

4) CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	(5) SOLE VOTING POWER 642,729
	(6) SHARED VOTING POWER 0
	(7) SOLE DISPOSITIVE POWER 357,834
	(8) SHARED DISPOSITIVE POWER 872,600

9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
1,236,314

10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN  
SHARES

11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
Less than 5%

12) TYPE OF REPORTING PERSON

HC

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
Under the Securities Exchange Act of 1934  
(Amendment No. 1)

DISCLAIMER: Information in this Schedule 13G is provided solely for the purpose of complying with Sections 13(d) and 13(g) of the Act and regulations promulgated thereunder, and is not to be construed as an admission that Wells Fargo & Company or any of its subsidiaries is the beneficial owner of the securities covered by this Schedule 13G for any purpose whatsoever.

Item 1(a) Name of Issuer:

Neurocrine Biosciences, Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:

10555 Science Center Drive  
San Diego, CA 92121

Item 2(a) Name of Person Filing:

Wells Fargo & Company

Item 2(b) Address of Principal Business Office:

Wells Fargo & Company  
420 Montgomery Street  
San Francisco, CA 94104

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form SC 13G/A

Item 2(c) Citizenship:

Delaware

Item 2(d) Title of Class of Securities:

Common Stock

Item 2(e) CUSIP Number:

64125C109

Item 3 The person filing is a:

Parent Holding Company in accordance with 240.13d-1(b)(1)(ii)(G)

Item 4 Ownership:

See Items 5-11 of each cover page.

Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be beneficial owners of more than five percent of the class of securities, check the following [ ].

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

See Attachment A.

Item 8 Identification and Classification of Members of the Group:

Not applicable.

Item 9 Notice of Dissolution of Group:

Not applicable.

Item 10 Certification:

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

Signature.

After reasonable inquiry and to the best of my knowledge and belief, I

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form SC 13G/A

certify that the information set forth in this statement is true,  
complete, and correct.

Date: April 16, 2001

WELLS FARGO & COMPANY

By: /s/ Laurel A. Holschuh  
Laurel A. Holschuh, Senior Vice President  
and Secretary

ATTACHMENT A

The Schedule 13G to which this attachment is appended is filed by Wells  
Fargo & Company on behalf of the following subsidiaries:

Peregrine Capital Management, Inc. (1)  
Wells Capital Management, Inc. (1)  
Wells Fargo Bank, N.A. (2)  
Wells Fargo Bank Minnesota, N.A. (2)

- 
- (1) Classified as a registered investment advisor in accordance with  
Regulation 13d-1(b)(1)(ii)(E).
- (2) Classified as a bank in accordance with Regulation  
13d-1(b)(1)(ii)(B).